Pembrolizumab in classical Hodgkin's lymphoma

Area of Science:

• Immunology
• Oncology
• Pharmacology

Background:

• Classical Hodgkin's lymphoma (cHL) features malignant Reed-Sternberg cells within an immune infiltrate.
• Upregulated PD-1 ligands on RS cells promote immune suppression via PD-1 interaction.
• PD-1 pathway dysregulation is implicated in tumor immune escape and T-cell exhaustion.

Purpose of the Study:

• To explore the rationale for targeting the PD-1 pathway in cHL.
• To review clinical trial data on checkpoint inhibitors in cHL.
• To present future research directions for PD-1 inhibition in cHL.

Main Methods:

• Review of scientific literature and clinical trial data.
• Analysis of the PD-1 pathway's role in cHL pathogenesis.
• Evaluation of pembrolizumab and nivolumab efficacy and safety.

Main Results:

• Pembrolizumab and nivolumab demonstrate significant activity in relapsed/refractory cHL.
• These PD-1 inhibitors show an acceptable toxicity profile.
• Immune-related adverse events associated with PD-1 blockade are generally manageable.

Conclusions:

• Targeting the PD-1 pathway is a promising strategy for cHL treatment.
• Checkpoint inhibitors offer a new therapeutic option for patients with relapsed/refractory cHL.
• Further investigation into PD-1 inhibition in cHL is warranted.